Advaxis, Inc. (NASDAQ:ADXS) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Tuesday.

Several other research analysts also recently weighed in on the stock. BidaskClub downgraded shares of Advaxis from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Cantor Fitzgerald set a $19.00 price target on shares of Advaxis and gave the stock a “buy” rating in a research report on Thursday, July 6th. Finally, HC Wainwright set a $23.00 price target on shares of Advaxis and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $22.00.

Shares of Advaxis (NASDAQ ADXS) opened at 6.23 on Tuesday. Advaxis has a 1-year low of $5.70 and a 1-year high of $16.30. The stock’s market cap is $252.08 million. The company has a 50 day moving average price of $6.62 and a 200 day moving average price of $7.99.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/10/advaxis-inc-nasdaqadxs-stock-rating-lowered-by-valuengine.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADXS. Northern Capital Management LLC increased its position in Advaxis by 14.6% in the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 2,650 shares during the period. State of Wisconsin Investment Board bought a new position in Advaxis during the second quarter valued at $201,000. Rhumbline Advisers increased its position in Advaxis by 3.7% in the second quarter. Rhumbline Advisers now owns 42,508 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 1,530 shares during the period. Schwab Charles Investment Management Inc. increased its position in Advaxis by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock valued at $840,000 after buying an additional 817 shares during the period. Finally, Stonebridge Capital Management Inc. bought a new position in Advaxis during the second quarter valued at $146,000. Hedge funds and other institutional investors own 54.95% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.